Glycominds is developing an additional prognostic test, the gMS^®Pro EDSS, to help physicians identify which Clinically Isolated Syndrome (CIS) or newly diagnosed Multiple Sclerosis (MS) patients will have a higher likelihood of progressing towards meaningful disabilities despite treatment. Physicians may want to consider more aggressive treatment for these patients.

 

Glycominds is developing an additional prognostic test, the gMS^®Pro EDSS, to help physicians identify which Clinically Isolated Syndrome (CIS) or newly diagnosed Multiple Sclerosis (MS) patients will have a higher likelihood of progressing towards meaningful disabilities despite treatment. Physicians may want to consider more aggressive treatment for these patients. The gMS^®Pro EDSS test will be targeted for use for diagnosed Multiple Sclerosis (MS) patients and potential MS patients who have had their first neurological event and will be starting therapeutic treatment for MS.

This test will be a panel of biomarkers specific to identifying patients who will progress towards higher EDSS scores despite treatment. The panel was studied in the BEtaferon^® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study. The gMS^®Pro EDSS panel studied the time to confirmed EDSS progression. The analysis demonstrated gMS^®Pro EDSS can significantly identify patients with higher risk for confirmed EDSS progression despite treatment within 5 years.

The company is continuing to do additional clinical studies to validate these results.

Currently there is no way to predict early after diagnosis whether a patient disease will progress despite treatment.

Epidemiological studies show: 
-30% of patients will not have meaningful disabilities (EDSS <3 after 20 years);
-45% of patients will have some meaningful disabilities (EDSS 3.0 within 20 years);
-25% of patients will have significant disabilities (EDSS 6.0 within 20 years) e.g. “fast”
In addition, clinical trials show that 40% of patients will respond well to therapy (both fast” and “slow” progressing patients) and 30% of patients are poor responders to current first line therapy.

The gMS^®Pro EDSS can identify patients with higher risk for confirmed EDSS progression in treatment within 5 years and help physicians also indentify patients who are likely to be “fast progressing” responders. This information will help physicians determine which patients to consider for more aggressive treatment.